Skip to main content

Abstract

Mesothelioma is a complex disease and manifests with physical and emotional symptoms as well as social issues. These symptoms and issues can be more burdensome to those with mesothelioma, family caregivers, and other carers than other diseases. One issue that is unfortunately common is that a patient or family member of this rare disease is often treated in a setting where there are few, if any, other patients with mesothelioma. This experience can exacerbate the symptoms and problems due to isolation, lack of support, and lack of specialized services. The process of this disease has additional layers of complexity as the vast majority of people diagnosed with mesothelioma were exposed at work and the reality that the current outcome of the disease is death. This chapter presents information on how people respond to an upcoming death, the actual dying process, and after the person with mesothelioma has died. This chapter includes the typical physical symptoms that are often the hallmark of the beginning of the end of life. Information about decisions that can be made to promote as much comfort care as possible at the end of life by both the patient and the caregiver is offered. The process that must be followed after death from mesothelioma, including information on whom to call and the differences between being in the United States vs. some countries in Europe, is presented in the Addendum. The goal of this chapter is to offer healthcare professional an understanding of what the end of the disease process might look like and how patients and their families may feel and concrete tasks that can be done in the least complicated and most sensitive manner.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • American Cancer Society. If treatment of malignant mesothelioma stops working. 2016. Available at: https://www.cancer.org/cancer/malignant-mesothelioma/after-treatment/no-longer-working.html. Accessed 1 Dec 2017.

  • British Lung Foundation. End of life with mesothelioma. 2017. Accessed 20 Nov 2017.

    Google Scholar 

  • Buchholz WM. The Patient’s experience of malignant mesothelioma. In: Testa J, editor. Asbestos and mesothelioma. Cham: Springer; 2017. p. 381–407.

    Chapter  Google Scholar 

  • Dooley JJ, Wilson JP, Anderson VA. Stress and depression of facing death: Investigation of psychological symptoms in patients with mesothelioma. Aust J Psychol. 2010;62(3):160–8.

    Article  Google Scholar 

  • Guirimand F, Sahut d’izarn M, Laporte L, Francillard M, Richard J, Aegerter P. Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer. Cancer Med. 2015;4(4):532–9.

    Article  Google Scholar 

  • Hartley K, Hesdorffer M. Challenges facing mesothelioma patients and their families: medical/legal intersections. In: Testa J, editor. Asbestos and mesothelioma. Cham: Springer; 2017. p. 359–81.

    Chapter  Google Scholar 

  • Hughes N, Arber A. The lived experience of patients with pleural mesothelioma. Int J Palliat Nurs. 2008;14(2):66–71.

    Article  Google Scholar 

  • Ionvno J. Mesothelioma statute of limitations. 2017. Accessed 10 Nov 2017.

    Google Scholar 

  • Kamal AH, Maguire JM, Wheeler JL, Currow DC, Abernethy AP. Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med. 2012;15(1):16–114.

    Article  Google Scholar 

  • Kirshbaum MN, Olson K, Pongthavornkamol K, Graffigna G. Understanding the meaning of fatigue at the end of life: an ethnoscience approach. Eur J Oncol Nurs. 2013;17(2):146.

    Article  Google Scholar 

  • Linton A, Pavlakis N, O’connell R, Soeberg M, Kao S, Clarke S, et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014;111(9):1860–9.

    Article  CAS  Google Scholar 

  • Lynn J, Harrold J, Schuster JL. Handbook for mortals: Guidance for people facing serious illness. 2nd ed. New York: Oxford University Press; 2011.

    Google Scholar 

  • Meyerhoff RR, Yang CJ, Speicher PJ, Gulack BC, Hartwig MG, D’Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196(1):23.

    Article  Google Scholar 

  • Moore S, Darlison L, Tod AM. Living with mesothelioma. A literature review. Eur J Cancer Care. 2010;19(4):458.

    Article  CAS  Google Scholar 

  • Musk AW, Olsen N, Alfonso H, Reid A, Mina R, Franklin P, et al. Predicting survival in malignant mesothelioma. Eur Respir J. 2011;38(6):1420–4.

    Article  CAS  Google Scholar 

  • National Cancer Institute. Planning the transition to end-of-life care in advanced cancer. 2015. Accessed 18 Nov 2017.

    Google Scholar 

  • National Comprehensive Cancer Network. Malignant pleural mesothelioma guideline for patients. 2016. Available at: https://www.nccn.org/patients/guidelines/mpm/files/assets/basic-html/page-1.html

  • National Comprehensive Cancer Network. Malignant pleural mesothelioma. 2017a. Accessed 7 Nov 2017.

    Google Scholar 

  • National Comprehensive Cancer Network. Cancer-related fatigue. 2017b. Accessed 18 Nov 2017.

    Google Scholar 

  • Quill TE, Byock IR, for the ACP-ASIM End-of-Life Care Consensus Panel. Responding to Intractable Terminal Suffering: The Role of Terminal Sedation and Voluntary Refusal of Food and Fluids. Ann Intern Med. 132:408–414. https://doi.org/10.7326/0003-4819-132-5-200003070-00012.

    Article  CAS  Google Scholar 

  • Taioli E, Wolf AS, Camacho-Rivera M, Kaufman A, Lee D, Nicastri D, et al. Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients. POLS One. 2015;10(12):e0145039.

    Article  CAS  Google Scholar 

  • van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karlynn BrintzenhofeSzoc .

Editor information

Editors and Affiliations

Addendum: End-Life-Care and the Legal Process

Addendum: End-Life-Care and the Legal Process

While the discussion on the legal process may not be germane to the direct care of mesothelioma patients due to the high mortality, elucidating the legal process as it relates to end-of-life care may be an important resource for patients and their families, because financial and legal matters may be important to maintaining quality of life for the patient and his family.

The information presented below should not be interpreted as legal advice. Healthcare professional should exercise caution when discussing the legal process with patients and their families.

1.1 Legal Process

As mesothelioma is most often the result of occupational exposure to asbestos, filing a claim for compensation is a common course of action. There is an abundance of law firms around the world who claim to focus specifically on working with people with mesothelioma. Be thoughtful about how you select your legal assistance. When filing a claim against a previous employer where the exposure took place, it doesn’t matter if the company knew they were putting employees at risk or not.

With the extended time between the exposure to asbestos and the diagnosis of mesothelioma, statutes of limitations have been revised to take this into account. The statutes of limitations are rules related to how long a person has before they must file a claim. In most cases, the time starts with exposure or when the injury took place. In the case of mesothelioma, the statute of limitations, which differs by state and the type of legal claim, the time to file ranges from 1 to 4 years from diagnosis (Hartley and Hesdorffer 2017).

There are three main routes to file a claim for the exposure that resulted in mesothelioma. The first is through a bankruptcy trust, the second is litigation, and, finally, if you are a veteran and you think your exposure was during your service, you would file veterans claim. A bankruptcy trust is a fund the companies where exposure to asbestos was known to have occurred were required to set up before they either close or claim bankruptcy to cover future legal claims. Litigation is when a lawsuit is filed with the intention of appearing in court. In many cases, these lawsuits can be settled out of court. A veteran who thinks they were exposed to asbestos while on active duty will file a claim for disability compensation through the Veterans Benefits Administration (https://www.benefits.va.gov/benefits/). You will also want to contact the VA Environmental Health Coordinator. You can find your local coordinator at https://www.publichealth.va.gov/exposures/asbestos/index.asp. There are two types of claims: personal injury and wrongful death.

When the person diagnosed with mesothelioma files a claim, it is a personal injury claim, within the statute of limitations for mesothelioma in the state you are filing. The claim can be filed to cover medical expenses, lost income (past, present, and future), and psychical and emotional pain. If the person with mesothelioma filed a claim after they were diagnosed and before they died, once the claim is settled, it becomes a part of the estate. This means that the executor of the estate will continue working with the lawyer the person with mesothelioma was working with to finalize the claim. There will likely be changes in what is covered once the person with mesothelioma dies. Since there will be no additional medical costs and the emotional distress does not continue beyond the death, the amount of the settlement may be impacted. Surviving family members can contact their local government office for state-specific information regarding legal proceedings and compensation (Hartley and Hesdorffer 2017).

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

BrintzenhofeSzoc, K., Daratsos, L. (2019). End-of-Life Care. In: Hesdorffer, M., Bates-Pappas, G. (eds) Caring for Patients with Mesothelioma: Principles and Guidelines. Springer, Cham. https://doi.org/10.1007/978-3-319-96244-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-96244-3_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-96243-6

  • Online ISBN: 978-3-319-96244-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics